2020
Cost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lung cancer patients in Asia.
Low J, Sooi K, Huang Y, Chan G, Ang Y, Chong W, Tan H, Ngoi N, Choo J, Lee M, Muthu V, Asokumaran Y, Walsh R, Wong R, Chan Z, Soo R, Sundar R, Yong W. Cost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lung cancer patients in Asia. Journal Of Clinical Oncology 2020, 38: e19385-e19385. DOI: 10.1200/jco.2020.38.15_suppl.e19385.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced non-small cell lung cancerProgression free survivalFree survivalFixed doseTreatment of non-small cell lung cancer patientsOncogenic driversNon-small cell lung cancer patientsTreatment of non-small cell lung cancerCell lung cancer patientsResponse rateTreated with pembrolizumabDose of pembrolizumabEfficacy of pembrolizumabKaplan Meier methodUS Food and Drug AdministrationSurvival of patientsCell lung cancerLow dose groupLung cancer patientsNational University HospitalFood and Drug AdministrationStandard of careECOG 0Overall survival
2019
Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer
Sundar R, Huang K, Qamra A, Kim K, Kim S, Kang W, Tan A, Lee J, Tan P. Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer. Annals Of Oncology 2019, 30: 424-430. PMID: 30624548, PMCID: PMC6442650, DOI: 10.1093/annonc/mdy550.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitionMetastatic gastric cancerT cell cytolytic activityResistance to immune checkpoint inhibitionCheckpoint inhibitionGastric cancerCytolytic activityImmune evasionMedian progression-free survivalPhase II clinical trial of patientsCancer treated with immunotherapyClinical trials of patientsMechanisms of immune evasionResponse rateTreated with pembrolizumabPhase II clinical trialProgression-free survivalFresh tumor biopsiesPost-treatment biopsiesCohort of patientsTrial of patientsEarly gastric cancerArchival tissue samplesClinical responseTumor biopsies